Analysts Set Expectations for MNPR FY2025 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Monopar Therapeutics in a research report issued on Monday, July 7th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($1.30) for the year. Cantor Fitzgerald has a “Overweight” rating and a $74.00 price objective on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Cantor Fitzgerald also issued estimates for Monopar Therapeutics’ FY2026 earnings at ($3.09) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.27.

Several other equities analysts have also weighed in on MNPR. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Piper Sandler reaffirmed an “overweight” rating and set a $76.00 target price on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Chardan Capital began coverage on shares of Monopar Therapeutics in a report on Monday, June 23rd. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, Jones Trading reiterated a “hold” rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Monopar Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $60.00.

Monopar Therapeutics Stock Performance

Shares of Monopar Therapeutics stock opened at $38.37 on Wednesday. The business’s 50 day moving average price is $35.84 and its 200 day moving average price is $35.28. The company has a market cap of $234.82 million, a price-to-earnings ratio of -11.03 and a beta of 1.01. Monopar Therapeutics has a one year low of $1.72 and a one year high of $54.30.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AlphaQuest LLC acquired a new stake in Monopar Therapeutics in the 1st quarter valued at about $44,000. JPMorgan Chase & Co. acquired a new stake in shares of Monopar Therapeutics during the fourth quarter worth about $45,000. Gerber LLC purchased a new stake in shares of Monopar Therapeutics in the 1st quarter valued at about $204,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Monopar Therapeutics in the 1st quarter valued at about $328,000. Finally, Jane Street Group LLC purchased a new position in Monopar Therapeutics during the 1st quarter worth approximately $377,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.